Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2…
<!-- Name:DistributionId Value:8807822 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Inozyme Pharma Inc.
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of…
- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate - - Company estimates…
Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal…
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of…
- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was generally well-tolerated and…
Inozyme Pharma Announces $73 Million Underwritten Offering Priced At-the-Market
BOSTON, April 14, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of…